Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. The company’s products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. Its lead drug include Triferic, an iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. The company also provides Calcitriol, a generic active vitamin D indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, it manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid concentrate, Renal Pure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company sells its products directly to hemodialysis providers, as well as through independent sales agents and distributors. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.